Molecular signatures and prognosis of hepatocellular carcinoma

Minerva Gastroenterologica e Dietologica

Volumn 57, Issue 3, 2011, Pages 311-322

  Hoshida, Y ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Carcinoma, hepatocellular; Gene expression; Prognosis

Indexed keywords

ALCOHOL; GENOMIC DNA; MESSENGER RNA; MYC PROTEIN; PROTEIN KINASE B; PROTEIN P53; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ASIAN; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CAUCASIAN; DIAGNOSTIC ACCURACY; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; ETHNICITY; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MOLECULAR DIAGNOSIS; MOLECULAR SIGNATURE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; GENES, MYC; GENES, P53; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 80755130237     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010; 15 Suppl 4: 5-13.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51. (Pubitemid 351323895)
3. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-36.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399);1907-5.
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis:incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50. (Pubitemid 39423368)
6. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S72-8. (Pubitemid 39423372)
7. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma:paradigms for viral-related human carcinogenesis. Oncogene 2006;25:3823-33. (Pubitemid 43980478)
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295:65-73. (Pubitemid 43042691)
9. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer:worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5-S16. (Pubitemid 39423365)
10. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
11. La Vecchia C. Alcohol and liver cancer. Eur J Cancer Prev 2007;16:495-7. (Pubitemid 350307497)
12. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection. Hepatology 2010;51:1820-32.
13. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S97-103.
14. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma:a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80. (Pubitemid 43343895)
15. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-41. (Pubitemid 37500438)
16. Bruix J, Sherman M. Management of hepatocellular carcinoma:An update. Hepatology 2011;53:1020-2.
17. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis:Implications for follow-up and screening. Hepatology 2008;48(3):863-70.
18. Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24(5):725-34.
19. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
20. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients:The French national Mortalite 2005 study. J Hepatol 2009;50:736-45.
21. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
22. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126:1005-14. (Pubitemid 38451172)
23. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48 Suppl 1.S20-37.
24. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular Classification and Novel Targets in Hepatocellular Carcinoma:Recent Advancements. Semin Liver Dis 2010;30:35-51.
25. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76. (Pubitemid 39265589)
26. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-6.
27. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-39. (Pubitemid 34651483)
28. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-9. (Pubitemid 36332108)
29. Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 2004;64:6058-64. (Pubitemid 39129404)
30. Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004;64:7263-70. (Pubitemid 39372063)
31. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.
32. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. (Pubitemid 46144363)
33. Lamb J. The Connectivity Map:a new tool for biomedical research. Nat Rev Cancer 2007;7:54-60. (Pubitemid 46020847)
34. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
35. Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma:putative therapeutic targets. Gastroenterology 2007;133:1475-86. (Pubitemid 350029748)
36. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73. (Pubitemid 32523494)
37. Uovet JM, Lok A. Hepatitis B virus genotype and mutants.risk factors for hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1121-3.
38. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-61. (Pubitemid 351346853)
39. Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (in press) 2011.
40. Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471-84.
41. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C et al. Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology 2011;140:1501-12.
42. Lee JS, Thorgeirsson SS. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002;35:1134-43. (Pubitemid 34454010)
43. Kawai HF, Kaneko S, Honda M, Shirota Y, Kobayashi K. alpha-fetoprotein- producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 2001;33:676-91. (Pubitemid 32185231)
44. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;26:774-80. (Pubitemid 46204256)
45. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med 2008;359:2045-7.
46. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47. (Pubitemid 46160989)
47. Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A et al. Inflammatory tumor microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010;52:370-9.
48. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009;206:1327-37.
49. Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518-27. (Pubitemid 38222194)
50. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
51. Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 2010;9:74.
52. Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T et al. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol 2006;13:947-54.
53. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111. (Pubitemid 44202603)
54. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010;70:10202-12.
55. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7. (Pubitemid 36169630)
56. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54. (Pubitemid 44970357)
57. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-41.
58. Kobayashi T, Itamoto T, Tashiro H, Amano H, Oshita A, Tanimoto Y et al. Tumor-related factors do not influence the prognosis of solitary hepatocellular carcinoma after partial hepatectomy. J Hepatobiliary Pancreat Sci 2011 [Epub ahead of print].
59. Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G et al. Increased GP73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol 2011.
60. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinomas systematic review of 72 studies. Liver Int 2009;29:502-10.
61. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R et al. New strategies in hepatocellular carcinoma:genomic prognostic markers. Clin Cancer Res 2010;16:4688-94.
62. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006;116:1582-95.
63. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47:2059-67. (Pubitemid 351945572)
64. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23. (Pubitemid 36460075)
65. Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004;41:284-91. (Pubitemid 39177633)
66. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008;14:2056-64. (Pubitemid 351551116)
67. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2010;70:3034-41.
68. Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 2007;13:6275-83. (Pubitemid 350075015)
69. Yoshioka S, Takemasa I, Nagano H, Kittaka N, Noda T, Wada H et al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 2009;45:881-9.
70. Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009;3:101-3.
71. Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 2003;39:215-21. (Pubitemid 36920557)
72. Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431-40.
73. Ng IO, Guan XY, Poon RT, Fan ST, Lee JM. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003;199:345-53. (Pubitemid 36266857)
74. Sakon M, Nagano H, Nakamori S, Dono K, Umeshita K, Murakami T et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy:analysis based on tumor hemodynamics. Arch Surg 2002;137:94-9. (Pubitemid 34041828)
75. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T et al. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma:a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol 2003;38:865-76. (Pubitemid 37322034)
76. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Gould J, Gupta S et al. Gene-expression signature predicts outcome of liver cirrhosis. Hepatology 2009;50:312A.
77. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. Jama 2008;299:53-60.
78. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ et al. A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma. Gastroenterology 2011 [Epub ahead of print].
79. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
80. Huang H, Shiftman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007;46:297-306. (Pubitemid 47344763)
81. Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009;50:1038-44.
82. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods 2004;1:155-61.
83. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007;7:36.
84. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009;15:5073-81.
85. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011;406:70-3.
86. Li W, Xie L, He X, Li J, Tu K, Wei L et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008;123:1616-22.
87. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009;361:1437-47.
88. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907. (Pubitemid 351449681)
89. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011;6.e16435.
90. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008;14:419-27. (Pubitemid 351226109)
91. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009;41:843-8.
92. Yoo CB, Jones PA. Epigenetic therapy of cancer:past, present and future. Nat Rev Drug Discov 2006;5:37-50.
93. Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010;5:e14460.
94. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117:2713-22. (Pubitemid 47494371)
95. Li B, Liu W, Wang L, Li M, Wang J, Huang L et al. CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Ann Surg Oncol 2010;17:1917-26.
96. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452:564-70. (Pubitemid 351483370)
97. Tan IB, Tan P. Genetics:An 18-gene signature (ColoPrint((R))) for colon cancer prognosis. Nat Rev Clin Oncol 2011;8:131-3.
98. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-14. (Pubitemid 40165374)
99. Lippman SM. The future of molecular-targeted cancer chemoprevention. Gastroenterology 2008;135:1834-41.